This data supports further investigation of the clinical utility of APRIL as a predictive biomarker for 5FU resistance in colorectal adenocarcinomas and other solid tumour types and also as a target for novel therapeutics aimed at reversal of clinical resistance to 5FU and its oral analogues. The gene discussed is TNFSF13; the disease is colorectal adenocarcinoma.